###begin article-title 0
###xml 11 16 11 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3</italic>
###xml 18 24 18 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC </italic>
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Osteosarcoma is a very aggressive tumor with a propensity to metastasize and invade surrounding tissue. Identification of the molecular determinants of invasion and metastatic potential may guide the development of a rational strategy for devising specific therapies that target the pathways leading to osteosarcoma.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 224 231 <span type="species:ncbi:9606">patient</span>
In this study, we used pathway-focused low density expression cDNA arrays to screen for candidate genes related to tumor progression. Expression patterns of the selected genes were validated by real time PCR on osteosarcoma patient tumor samples and correlated with clinical and pathological data.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3</italic>
###xml 7 13 7 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC </italic>
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 104 110 104 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3 </italic>
###xml 387 393 387 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3 </italic>
###xml 432 438 432 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC </italic>
###xml 640 645 640 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 183 191 <span type="species:ncbi:9606">patients</span>
###xml 350 358 <span type="species:ncbi:9606">patients</span>
###xml 513 521 <span type="species:ncbi:9606">patients</span>
THBS3, SPARC and SPP1 were identified as genes differentially expressed in osteosarcoma. In particular, THBS3 was expressed at significantly high levels (p = 0.0001) in biopsies from patients with metastasis at diagnosis, which is a predictor of worse overall survival, event-free survival and relapse free survival at diagnosis. After chemotherapy, patients with tumors over-expressing THBS3 have worse relapse free survival. High SPARC expression was found in 51/55 (96.3%) osteosarcoma samples derived from 43 patients, and correlated with the worst event-free survival (p = 0.03) and relapse free survival (p = 0.07). Overexpression of SPP1 was found in 47 of 53 (89%) osteosarcomas correlating with better overall survival, event-free survival and relapse free survival at diagnosis.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 312 318 312 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3 </italic>
###xml 386 392 386 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3 </italic>
###xml 446 452 446 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC </italic>
###xml 543 548 543 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
In this study three genes were identified with pattern of differential gene expression associated with a phenotypic role in metastasis and invasion. Interestingly all encode for proteins involved in extracellular remodeling suggesting potential roles in osteosarcoma progression. This is the first report on the THBS3 gene working as a stimulator of tumor progression. Higher levels of THBS3 maintain the capacity of angiogenesis. High levels of SPARC are not required for tumor progression but are necessary for tumor growth and maintenance. SPP1 is not necessary for tumor progression in osteosarcoma and may be associated with inflammatory response and bone remodeling, functioning as a good biomarker.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 214 215 214 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 373 374 373 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 479 480 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 570 571 570 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 37 45 <span type="species:ncbi:9606">children</span>
###xml 427 435 <span type="species:ncbi:9606">patients</span>
Osteosarcoma (OS) is a rare tumor of children and young adults. The peak of incidence occurs in the second decade of life [1]. In Brazil, it is estimated that a total of 350 new cases of OS are diagnosed per year [2], with metastasis in 20.9% of the cases. The presence of metastases at diagnosis is the most significant isolated factor influencing survival in this group [3]. Lung metastases appear in almost 40 to 50% of the patients with OS, and are the major cause of death [4]. The degree of necrosis following definitive surgery is a consistent prognostic factor [5].
###end p 11
###begin p 12
###xml 364 365 364 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 565 566 565 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
Metastases consist of a series of sequential steps, all of which must be successfully completed. These include shedding of cells from a primary tumor into the circulation, survival of the cells in the circulation, arrest in a new organ, extravasations into the surrounding tissue, initiation and maintenance of growth, and vascularization of the metastatic tumor [6]. The successful metastatic cells must possess a set of particular characteristics that are different from non-metastatic tumor cells, enabling them to complete each step in the metastatic sequence [7].
###end p 12
###begin p 13
###xml 262 263 262 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 293 297 293 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 421 422 419 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 423 424 421 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 631 633 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 634 636 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
Knowledge on the biology of the metastatic process is limited. Some molecular factors have been identified as contributing to the formation of detectable metastases, and additional factors hopefully will be soon identified using microarray expression profiling [6]. The pathway-focused GEArray(R) is a useful way to perform both highly sensitive and precise large-scale analysis of the expression level of various genes [8,9]. The advantage of using this technology is that a defined set of genes closely-related to a specific process, biological behavior or biomarker can be screened with limited sample material, as observed by [10-12]. Through these comparisons, a list of genes differentially expressed and potentially important for the process is easily derived that can be validated by other techniques. The biomarkers may become tools for establishing early diagnosis and designing therapeutic targets in specific cancers.
###end p 13
###begin p 14
###xml 120 125 120 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 214 220 214 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ITGB4 </italic>
###xml 238 243 235 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTGF </italic>
###xml 278 284 275 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ITGA5 </italic>
###xml 303 308 296 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VIL2 </italic>
###xml 317 323 310 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ITGB2 </italic>
###xml 341 348 331 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LGALS3 </italic>
###xml 362 368 352 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADAM8 </italic>
###xml 414 418 404 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CLU </italic>
###xml 431 437 421 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FARP1 </italic>
###xml 438 442 428 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FERM</italic>
###xml 444 450 434 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RhoGEF</italic>
###xml 499 502 489 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CP </italic>
###xml 613 615 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 48 54 <span type="species:ncbi:10090">murine</span>
By comparing the highly metastatic K7M2 and K12 murine osteosarcoma cell lines using cDNA microarray technology, Khanna et al. [13] identified 10 potential genes involved in the metastatic process in osteosarcoma: ITGB4 (integrin beta4), CTGF (connective tissue growth factor), ITGA5 (integrin alpha5), VIL2 (ezrin), ITGB2 (integrin beta2), LGALS3 (galectin-3), ADAM8 (a disintegrin and metalloprotease domain 8), CLU (clusterin), FARP1 (FERM, RhoGEF, and pleckstrin domain protein 1 isoform 1) and CP (ceruloplasmin). These genes are involved in motility/cytoskeleton, heterotypic adherence and/or angiogenesis [13].
###end p 14
###begin p 15
Genes identified in this work include those not described previously in OS as well as potentially novel metastasis-associated genes. Functional studies suggest that 10 genes associated with motility/cytoskeleton, heterotypic adherence, and angiogenesis are most likely associated with differences in the metastatic behavior of the high and low metastatic OS models.
###end p 15
###begin p 16
###xml 50 54 50 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 110 115 108 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3</italic>
###xml 117 123 115 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC </italic>
###xml 127 132 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
In this study, we used the pathway-focused GEArray(R) technique to screen genes related to tumor progression. THBS3, SPARC and SPP1 were identified by cDNA array as genes differentially expressed in osteosarcoma. In addition, expression of selected genes was significantly correlated with clinico-pathological data.
###end p 16
###begin title 17
Methods
###end title 17
###begin title 18
Sample collection
###end title 18
###begin p 19
###xml 231 238 <span type="species:ncbi:9606">patient</span>
Seventy-six OS tumor samples were obtained at the Instituto de Oncologia Pediatrica, Grupo de Apoio ao Adolescente e a Crianca com Cancer/Universidade Federal de Sao Paulo (IOP/GRAACC/UNIFESP, Sao Paulo, SP, Brazil), with informed patient consent and approval of the institutional research ethics board (0261/03). Tissue sections were stained and subjected to standard histopathological evaluation to determine tumor content, as well as the proportion of necrosis and the pathological grade. Tumor specimens were stored at -80degreesC until a tumor-rich tissue had been selected for RNA extraction, according to the histological assessment by the pathologist. Clinical data for each case was obtained from the medical records.
###end p 19
###begin title 20
Diagnostic staging and treatment
###end title 20
###begin p 21
###xml 198 199 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 254 256 254 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 339 341 339 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 458 460 458 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 601 602 601 602 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 736 738 736 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 763 764 763 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 215 223 <span type="species:ncbi:9606">patients</span>
###xml 970 977 <span type="species:ncbi:9606">patient</span>
All patients younger than 25 years of age with high-grade OS of the extremities (metastatic and non-metastatic) were prospectively enrolled onto the Brazilian Osteosarcoma Treatment Group study IV [3]. In study IV, patients received carboplatin (500 mg/m2 intravenous infusion on day 1 of weeks 0, 3, 6, 17, and 26) and cisplatin (100 mg/m2 intravenous infusion on day 1 of weeks 0, 3, 6, 11, and 20). Doxorubicin was administered either at a dose of 30 mg/m2 in short-term intravenous infusion on days 1 and 2 of weeks 0, 3, 6, 14, 17, and 23 in the initial phase of the study or at a dose of 35 mg/m2, following the same schedule administered in a previous group with dexrazoxane. Intravenous infusion infusions of ifosfamide at 3 g/m2 and mesna, as described [3] were added on days 1, 2, and 3 and on weeks 11, 14, 20, and 26, respectively. The orthopedics team in collaboration with the pediatric oncology team determined the appropriate surgical procedure for each patient. Non-conventional endoprosthesis, resection of expendable bones, plaques, and bone graft fixation (autograft or bone bank) were used. Whenever possible, all pulmonary metastases were surgically removed, after resection of the primary tumor.
###end p 21
###begin title 22
RNA preparation
###end title 22
###begin p 23
###xml 54 58 54 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
Total RNA from OS tumors was isolated using the TRIzol(R) Reagent (Invitrogen) and re-suspended in sterile DEPC water. The amount of RNA was determined by spectrophotometry and sample integrity was monitored through visualization of ribosomal RNAs (28S and 18S) by electrophoresis.
###end p 23
###begin title 24
Gene expression profiling
###end title 24
###begin p 25
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 284 292 <span type="species:ncbi:9606">patients</span>
Pathway-focused expression profiling was performed using a subset of 15 tumors: 9 samples from patients with metastatic disease at diagnosis (3 initial biopsy specimens, 3 primary bone tumor resection specimens, and 3 biopsies of metastasis detected at diagnosis); and 6 samples from patients classed as having non-metastatic disease at diagnosis (3 initial biopsy specimens and 3 primary bone tumor resection specimens). For each group, a pool of an equal amount of RNA from 3 tumor samples from each phase of disease was used. In addition, a pool of RNA derived from osteoblastic cellular preparations from two bone resections unrelated to a pathological condition served as a tissue-specific expression control.
###end p 25
###begin p 26
###xml 7 11 7 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 240 244 238 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 720 722 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 145 150 <span type="species:ncbi:9606">human</span>
###xml 253 258 <span type="species:ncbi:9606">Human</span>
GEArray(R) Q Series pathway arrays containing 112 sites each (3 blanks, 3 negative reference spots, 10 endogenous genes, and 96 pathway-specific human genes) were obtained from SuperArray Bioscience Corporation (Frederick, USA). The GEArray(R) Q Series Human Tumor Metastasis Gene Array, Chemokines and Receptors Gene Array and Angiogenesis Gene Array were designed to assess the different expression levels of 96 genes that either interact with or are controlled by each specific biological pathway. Protocol and data analysis of arrays were performed according to the manufacturer's instructions and the gene list and array position for expression profiling are available at Superarray Bioscience Corporation website [14].
###end p 26
###begin p 27
###xml 97 101 96 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 157 160 154 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 616 619 605 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
Biotin-labeled cDNA were generated with total RNA (1mug) from corresponding samples using GEArray(R) Ampolabelling LPR Kit (SuperArray Bioscience Corporation(R)). The cDNA probes were then denatured, and hybridized in GEAhyb solution to nylon membranes spotted with gene-specific fragments. Hybridization was performed over-night at 60degreesC with continuous agitation. Membranes were washed twice in 2 x SSC/1%SDS for 15 minutes each, followed by another wash in 0.1 x SSC/0.5%SDS for 15 minutes. Hybridized probes were visualized with the CPD-Star Chemiluminescent Detection Kit (SuperArray Bioscience Corporation(R)).
###end p 27
###begin p 28
###xml 349 353 349 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 413 416 411 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 488 493 484 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB </italic>
Array images were recorded using Kodak X-OMAT LS film (Amersham Biosciences, Piscataway, NJ, USA) and SprintScan 35 Plus (Polaroid Canada Inc., Mississauga, ON, Canada). Images were converted into grayscale and 16-bit tiff format, and the numerical data representing the expression levels of each gene on the arrays were quantified using the GEArray(R) Expression Analysis Suite (SuperArray Bioscience Corporation(R)). Raw data were intra-normalized with the mean signal intensity of the ACTB gene after subtracting the mean intensities of the negative control spots (pUC18 plasmid DNA and blank spots. Inter-normalization was performed with control normal bone signal intensities.
###end p 28
###begin p 29
###xml 221 228 221 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 319 326 319 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 403 410 403 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 488 495 488 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 590 597 590 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 183 191 <span type="species:ncbi:9606">patients</span>
###xml 281 289 <span type="species:ncbi:9606">patients</span>
###xml 366 373 <span type="species:ncbi:9606">patient</span>
###xml 446 454 <span type="species:ncbi:9606">patients</span>
###xml 548 556 <span type="species:ncbi:9606">patients</span>
The change in the level of a given gene transcript from one membrane/experiment was estimated by comparing the signal intensities of paired specimens, such as: (1) biopsy sample from patients with metastasis at diagnosis versus normal bone; (2) primary tumor resection sample from patients with metastasis at diagnosis versus normal bone; (3) metastatic sample from patient with metastasis at diagnosis versus normal bone; (4) biopsy sample from patients with non metastasis at diagnosis versus normal bone; (5) primary tumor resection sample from patients with non metastasis at diagnosis versus normal bone. The differentially expressed genes were determined based on two criteria: gene performance outline filtering was applied to exclude the lower intensity or absent values, and only genes with fold changes larger than -2 and +2 were considered for increased/decreased expression.
###end p 29
###begin p 30
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
The expression datasets presented in this publication have been deposited in NCBIs Gene Expression Omnibus [15] and are accessible through GEO Series accession number GSE5045.
###end p 30
###begin title 31
Quantitative real-time PCR
###end title 31
###begin p 32
###xml 189 195 189 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3 </italic>
###xml 249 255 249 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC </italic>
###xml 313 318 313 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 18 26 <span type="species:ncbi:9606">patients</span>
###xml 239 247 <span type="species:ncbi:9606">patients</span>
###xml 299 307 <span type="species:ncbi:9606">patients</span>
###xml 362 370 <span type="species:ncbi:9606">patients</span>
From 43 different patients, 20 biopsies, 22 primary tumors, and 19 metastases specimens were included for real-time PCR analysis. Due to low quantity of RNA, the relative quantification of THBS3 was performed on 52 samples derived from 40 patients, SPARC was performed on 55 samples derived from 43 patients, and SPP1 was performed on 53 samples derived from 41 patients.
###end p 32
###begin p 33
###xml 52 56 52 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 96 99 94 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 153 155 149 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 205 208 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 220 225 214 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3</italic>
###xml 226 231 220 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC</italic>
###xml 233 238 227 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 269 274 260 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB </italic>
###xml 446 449 437 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 504 508 492 494 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 549 552 535 536 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 214 219 <span type="species:ncbi:9606">human</span>
Total RNA was reverse-transcribed using the Gene Amp(R) Gold RNA PCR Core Kit (Applied Biosystem(R)) according to the manufacturer's instructions. The RT2 PCR Primer Sets (SuperArray Bioscience Corporation(R)) for human THBS3,SPARC, SPP1 (target genes) and beta-actin (ACTB - endogenous gene) were used. Real-time PCR amplification and data analysis were performed using the ABI Prism 7900 and 7700 HT Sequence Detector System (Applied Biosystems(R)). Each sample was mixed with 24mul of master mix (SYBR(R) Green PCR Master Mix - Applied Biosystems(R)). The PCR conditions were 2 minutes at 50degreesC, 10 minutes at 95degreesC, followed by 40 cycles of 15 seconds at 95degreesC and 1 minute at 60degreesC. Experiments were performed in triplicate, for both the target and the endogenous genes. A no-template control was included in each amplification reaction. The PCR efficiencies of the four genes were comparable (>/= 95%).
###end p 33
###begin title 34
Real-time PCR data analysis
###end title 34
###begin p 35
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 287 291 284 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB</italic>
###xml 499 504 492 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB </italic>
###xml 860 873 837 842 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-&#916;&#916;Ct</sup>
###xml 626 631 <span type="species:ncbi:9606">Human</span>
To determine the relative quantification of gene expression, the comparative Ct (cycle threshold) method was used [16]. Briefly, this method uses arithmetic formulas to determine relative quantification. To normalize the varying cDNA quantities, an endogenous control gene (beta-actin - ACTB) was run concurrently with the target gene. For each sample, the Ct was determined for both the target gene and the endogenous gene (median of the 3 reactions). The DeltaCt was determined by subtracting the ACTB Ct from the specific target gene Ct. Identical calculations were made for a known positive control reference sample (QPCR Human Reference Total RNA, Stratagene, La Jolla, CA, USA). The DeltaCt of the control reference was then subtracted from the DeltaCt of the target gene, yielding the DeltaDeltaCt, and the relative quantitative value was expressed as 2-DeltaDeltaCt.
###end p 35
###begin title 36
Statistical analysis
###end title 36
###begin p 37
###xml 607 615 <span type="species:ncbi:9606">patients</span>
Data analysis was performed using Minitab Statistical Software (14.0). Clinical variables correlated with gene expression were: age at diagnosis, gender, histological OS subtype, site of the primary disease, metastatic status at diagnosis, response to chemotherapy, and type of samples (initial biopsy, primary bone tumor resection and metastasis sample present at diagnosis). Overall survival was defined as the time from diagnosis until the date of either the last follow-up or death. The duration of event-free survival was defined as the time from diagnosis until the date of relapse or death. If these patients had metastatic disease at diagnosis, the event was considered as time 0. For the relapse free survival analysis, the duration was defined as the time from diagnosis until the occurrence of metastasis or local relapse.
###end p 37
###begin p 38
###xml 476 479 476 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chi</italic>
All samples from each biopsy, primary tumor resection, and at metastasis were evaluated using gene expression profile findings, and these variables were correlated with survival. Overall survival, event-free survival and relapse-free survival curves were generated by applying the Kaplan-Meier method, and were then compared by the log-rank test. Continuous data were evaluated and compared using ANOVA, Mann-Whitney or Mood's Median test. Categorical data were studied using Chi-square or Fisher exact tests. Statistical significance was taken as p < 0.05.
###end p 38
###begin title 39
Results
###end title 39
###begin p 40
###xml 84 85 84 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 156 161 156 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3</italic>
###xml 163 169 163 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC </italic>
###xml 173 178 173 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
A summary of the clinico-pathological parameters for each case is detailed in Table 1. There was no significant difference in relative expression levels of THBS3, SPARC and SPP1 when the initial biopsy specimens, the primary bone tumor resection specimens, and the biopsies of metastasis were compared. Therefore we examined differential levels of gene expression of all three genes in primary tumor RNA (from both biopsy specimens and bone tumor resections) to assess their utility as biomarkers of prognosis. Thus in these analyses expression levels in primary tumor RNA were used as predictors of overall survival, event-free survival and relapse-free survival.
###end p 40
###begin title 41
###xml 23 27 23 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
Pathway-focused GEarray(R) analysis
###end title 41
###begin p 42
###xml 201 205 201 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 515 520 513 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3</italic>
###xml 522 527 520 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC</italic>
###xml 529 538 527 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">and SPP1 </italic>
###xml 567 568 565 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 747 749 745 747 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 214 219 <span type="species:ncbi:9606">Human</span>
Samples from biopsy, primary tumor resection and metastatic site (metastatic group only) from the metastatic and non-metastatic groups were each processed for gene expression analysis using the GEArray(R) Q Series Human Tumor Metastasis Gene Array, Chemokines and Receptors Gene Array, and Angiogenesis Gene Array. Thirty-two genes from the angiogenesis membrane, 51 from the tumor metastasis membrane and 25 genes from the chemokine membrane were identified as differentially expressed. The values of the selected THBS3, SPARC, and SPP1 genes are presented in Table 2. Correlation coefficients did not detect any relationship between the relative expression levels of these genes considered at any time point or in combination (-0.11 < Adjusted R2 < 0.14).
###end p 42
###begin title 43
###xml 38 46 <span type="species:ncbi:9606">patients</span>
THBS3 mRNA expression in osteosarcoma patients
###end title 43
###begin p 44
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3 </italic>
###xml 168 174 168 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3 </italic>
###xml 220 225 220 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3</italic>
###xml 247 253 247 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3 </italic>
###xml 281 288 281 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 486 493 486 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 561 567 561 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3 </italic>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 639 647 <span type="species:ncbi:9606">patients</span>
To confirm THBS3 over-expression, we performed quantitative real-time PCR on 52 samples from 40 patients. Of the 52 tumors analyzed, 30 (58%) showed high expression of THBS3 and 22 samples (42%) showed low expression of THBS3. A comparison of the THBS3 expression levels in biopsy versus primary tumor resection or metastatic samples showed significant differences (p = 0.0001, p = 0.0001, respectively). However, this correlation was not significant in primary tumor resection samples versus metastases (p = 0.72) (Figure 1A). In addition, different levels of THBS3 expression were observed when biopsy and surgical samples from the same patients were compared (n = 7) (p = 0.031).
###end p 44
###begin p 45
###xml 375 381 375 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3 </italic>
###xml 422 425 422 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 595 597 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 635 641 633 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3 </italic>
###xml 697 700 695 698 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 751 758 747 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 830 832 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 59 67 <span type="species:ncbi:9606">patients</span>
###xml 325 333 <span type="species:ncbi:9606">Patients</span>
###xml 600 608 <span type="species:ncbi:9606">Patients</span>
A trend for higher expression was observed in samples from patients with metastatic disease at diagnosis (p = 0.058). However, there was no significant correlation with other clinical parameters, such as age at diagnosis, gender, Huvos grade, site of primary tumor, histological type and presence of metastasis at diagnosis. Patients with OS and high levels of expression of THBS3 in biopsy samples stratified using the 75th percentile as cutoff value (>/= 1.0), showed worse overall survival (p = 0.03), event-free survival (p = 0.02) and relapse free survival at diagnosis (p = 0.003) (Figure 2A). Patients containing high levels of THBS3 expression in surgical specimens stratified using the 50th percentile as cutoff value (>/= 0, over-expression versus down-expression), showed worse relapse free survival (p = 0.05) (Figure 2A).
###end p 45
###begin title 46
###xml 38 46 <span type="species:ncbi:9606">patients</span>
SPARC mRNA expression in osteosarcoma patients
###end title 46
###begin p 47
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC </italic>
###xml 129 135 129 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC </italic>
###xml 185 191 185 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC </italic>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 557 563 557 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC </italic>
###xml 602 605 602 605 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 734 736 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 528 536 <span type="species:ncbi:9606">Patients</span>
To confirm SPARC over-expression, we performed quantitative real-time PCR on 55 samples from 43 patients. High expression of the SPARC gene was found in 51 of 55 tumor samples (96.3%). SPARC over-expression did not correlate with the different periods of disease (biopsy, surgery and metastasis) (Figure 1B), presence of metastasis at diagnosis, and the clinico-pathological parameters, such as Huvos grade, age, gender, histological OS subtype, site of primary disease, as well as, the overall survival (p = 0.81) (Figure 2B). Patients with high levels of SPARC gene expression stratified using the 75th percentile as cutoff value (>/= 1.5), revealed worse event-free survival (p = 0.03) and relapse free survival (p = 0.07) (Figure 2B).
###end p 47
###begin title 48
###xml 37 45 <span type="species:ncbi:9606">patients</span>
SPP1 mRNA expression in osteosarcoma patients
###end title 48
###begin p 49
###xml 11 16 11 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 109 114 109 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 527 529 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 566 572 566 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3 </italic>
###xml 703 708 703 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 969 974 969 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 1016 1019 1016 1019 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 1180 1182 1178 1180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 673 681 <span type="species:ncbi:9606">patients</span>
###xml 915 923 <span type="species:ncbi:9606">Patients</span>
To confirm SPP1 over-expression, we performed quantitative real-time PCR on 53 samples from 41 patients. The SPP1 gene was over-expressed in 47 of 53 (89%) and under-expressed in 6/53 (11%) of OS samples. In addition, there was a significantly greater level of SPP1 in biopsy samples than in both primary tumor resections and metastatic samples (p = 0.002, p = 0.0002, respectively). However, SPP1 expression levels did not reach significance when primary tumor resection samples were compared to metastases (p = 0.11) (Figure 1C). A recurrent differential level of THBS3 expression was also observed when comparing biopsy and primary tumor resection samples from the same patients (n = 7) (p = 0.031). SPP1 over-expression did not correlate with the presence of metastasis at diagnosis and the clinico-pathological parameters, such as Huvos grade, age, gender, histological OS subtype and site of primary disease. Patients with OS showing high levels of expression of SPP1 in biopsy samples, stratified using the 25th percentile as cutoff value (>/= 1.1), revealed better overall survival (p = 0.001), event-free survival (p = 0.02) and relapse free survival (p = 0.005) (Figure 2C).
###end p 49
###begin title 50
Discussion
###end title 50
###begin p 51
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3</italic>
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC </italic>
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 79 83 79 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
In this study, THBS3, SPARC and SPP1 were identified by pathway-focused GEArray(R) as genes differentially expressed in OS.
###end p 51
###begin p 52
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3</italic>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 13 18 <span type="species:ncbi:9606">human</span>
The gene for human thrombospondin 3 (THBS3) is a member of a family that encodes an extracellular matrix glycoprotein mediating interactions between cells and the extracellular matrix [17,18]. The thrombospondin family of proteins has been implicated in a number of fundamental biological processes: blood coagulation, embryonic development, tissue differentiation, tumor growth and metastases, angiogenesis, nerve development, wound healing, and inflammation [17-19].
###end p 52
###begin p 53
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC</italic>
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 469 471 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
Osteonectin (SPARC) is a 32kDa protein important for bone calcification [20]; it is a multifunctional glycoprotein that belongs to the matricellular proteins, defined as a group of extracellular regulatory macromolecules relevant to the extracellular matrix structure [21]. It is involved in a variety of biological processes including tissue remodeling, cell adhesion, proliferation, differentiation, matrix synthesis, angiogenesis, tumor cell migration and invasion [22,23].
###end p 53
###begin p 54
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 500 502 500 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
The SPP1 gene (osteopontin) is a non-collagenous bone matrix protein with several functions, such as bone remodeling, angiogenesis, cell adhesion, tumor migration and invasion [24-26]. The functional diversity of osteopontin in bone has many features in common with the repair processes involved in inflammatory responses [27]. It is produced by numerous cell types, osteoblasts, osteoclasts, T lymphocytes, NK cells and epithelial cells from breast, kidney, skin, nerve cells and endothelial cells [24-26].
###end p 54
###begin p 55
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
Invasion and metastases are inherent features of malignant diseases and involve both intercellular and cell-matrix interaction. The molecular mechanisms include transcriptional modulation of adhesive and anti adhesive molecules, proteases and angiogenic factors [28].
###end p 55
###begin p 56
###xml 666 667 666 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
As a primary tumor grows, it needs to develop a blood supply that can support its metabolic needs - angiogenesis. These new blood vessels may also provide an escape route by which cells can leave the tumor and enter into the body's circulatory blood system, a process known as "intravasation". The cells need to survive in the circulation until they are arrested in a new organ; where they may extravasate from the circulation into the surrounding tissue. Once in the new site, cells must initiate and maintain growth to form pre-angiogenic micrometastases; this growth must be sustained by the development of new blood vessels in order to form a macroscopic tumor [6].
###end p 56
###begin p 57
###xml 81 85 81 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMP</italic>
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS5</italic>
###xml 134 139 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3</italic>
###xml 184 190 184 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3 </italic>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 257 262 257 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS1</italic>
###xml 370 376 370 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS1 </italic>
###xml 475 477 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 478 480 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 619 621 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 648 654 648 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS1 </italic>
###xml 800 802 800 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 145 149 <span type="species:ncbi:10090">mice</span>
###xml 234 238 <span type="species:ncbi:10090">mice</span>
Thrombospondin 3 is structurally similar to cartilage oligomeric matrix protein (COMP/THBS5), but its function is unknown. A study in THBS3-null mice provided evidence for the role of THBS3 in the regulation of skeletal maturation in mice [29]. The role of THBS1, the most widely studied gene in this family, in angiogenesis and tumor progression remains controversial. THBS1 has been considered an inhibitor of angiogenesis and tumor progression in bladder and lung cancer [30,31]. In contrast, it has also been considered a stimulator of both processes in pancreatic carcinoma, melanoma and hepatocellular carcinoma [32-34]. One study found high THBS1 levels in hepatocellular carcinoma and venous invasion in tumors with low levels of vascular endothelial growth factor (VEGF) protein expression [34].
###end p 57
###begin p 58
###xml 61 67 61 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3 </italic>
###xml 210 216 210 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3 </italic>
###xml 494 500 494 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3 </italic>
###xml 567 572 567 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3</italic>
###xml 398 406 <span type="species:ncbi:9606">patients</span>
The group with metastasis at diagnosis showed high levels of THBS3 expression in biopsy samples, demonstrating the importance of this gene in tumor growth and progression. These data strongly suggest that high THBS3 expression can predict worse overall survival, event-free survival and relapse free survival at diagnosis. After chemotherapy, levels of THBS3 declined in some tumors. The groups of patients who maintain over expression have worse relapse free survival, suggesting that keeping THBS3 at high levels maintains the capacity of angiogenesis activated by THBS3. This is part of the process of tumor progression and perhaps may be used as a prognostic factor and therapeutic target in OS.
###end p 58
###begin p 59
###xml 65 71 65 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3 </italic>
###xml 166 171 166 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS1</italic>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 378 384 378 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3 </italic>
To the best of our knowledge, this is the first report about the THBS3 gene function as a stimulator of tumor progression in osteosarcoma. Its effects, like those of THBS1, may also depend on concentration, type of domain activated or available, and type of receptors present on endothelial cells [33,35,36]. The study of these parameters together with the expression levels of THBS3 in OS should be considered, given one's interest in anti-angiogenic agents in the OS treatment protocol.
###end p 59
###begin p 60
###xml 61 63 61 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC </italic>
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
Osteonectin is produced by osteoblasts and young osteocytes [37]. SPARC is expressed at high levels in bone tissue [38].
###end p 60
###begin p 61
###xml 168 174 168 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC </italic>
###xml 230 236 230 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC </italic>
###xml 368 374 366 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC </italic>
In this study no differences were observed between the levels of expression in biopsy, primary tumor resection and metastatic site samples, showing that high levels of SPARC are not required for tumor progression. However, higher SPARC expression (>/= 1.5) has worse event-free survival and shows a tendency to early relapse free survival. This strongly suggests that SPARC expression is necessary for tumor growth and maintenance, and may be used as a promising prognostic marker in OS.
###end p 61
###begin p 62
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC </italic>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 228 234 228 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC </italic>
###xml 349 351 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 80 85 <span type="species:ncbi:9606">human</span>
###xml 306 311 <span type="species:ncbi:9606">human</span>
Over-expression of SPARC promotes tumor growth and was reported in a variety of human malignancies, including melanoma, breast cancer, esophageal cancer and gastric carcinoma [28,39-41], but other reports suggest that decreased SPARC expression is associated with increased tumorigenesis and metastases in human ovarian carcinoma and neuroblastoma [42,43]. The promoting or inhibiting effects of osteonectin in different cancers seem dependent upon the cell type, the concentration, and the presence of full-length or proteolytic fragments of osteonectin [44].
###end p 62
###begin p 63
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1</italic>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 176 181 176 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 287 289 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 273 278 <span type="species:ncbi:9606">human</span>
Osteopontin (SPP1) is a major protein of the extracellular bone matrix, and gene expression is up regulated in specific phases of osteoblastic lineage differentiation [45-47]. SPP1 has become of interest in tumorigenesis, and expression of the protein has been observed in human cancer [48].
###end p 63
###begin p 64
###xml 72 77 72 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 163 168 163 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 413 418 413 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 518 523 518 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 691 693 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 694 696 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 755 760 755 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 939 944 939 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 948 952 948 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VEGF</italic>
###xml 963 968 963 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 1044 1049 1044 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 1181 1183 1181 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 1214 1219 1214 1219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 1477 1479 1477 1479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 878 886 <span type="species:ncbi:9606">patients</span>
In this study, we observed that biopsy samples had higher expression of SPP1 than samples from primary tumor resection and metastasis, showing that high levels of SPP1 are not necessary for tumor progression in OS. At the same time, we noticed that the level of expression is an independent variable from the presence of metastatic disease at diagnosis; these two characteristics indicate that high expression of SPP1 is not necessary for tumor progression or metastatic disease in OS. In contrast, high expression of SPP1 in other tumors, such as breast cancer, lung cancer, prostate cancer, hepatocellular carcinoma, colon cancer has been associated with tumor progression and metastases [49-52]. Another contrast is that we observed over expression of SPP1 correlates with better overall survival, event-free survival and relapse free survival. A study of 57 samples from OS patients by immunohistochemistry reported over expression of SPP1 and VEGF. However, SPP1 levels showed no correlation with overall survival and event-free survival. SPP1 is normally expressed in normal bone and, as part of the inflammatory response, participates in the remodeling process of the bone [53]. The functional diversity of SPP1 in bone formation and remodeling appears to be related to the fundamental roles of this protein in host defense and tissue repair; in fact, the bone remodeling process has many features in common with the repair processes involved in inflammatory responses [27].
###end p 64
###begin p 65
Identification of the molecular determinants of invasion and metastatic pathways will guide the development of a rational strategy for devising specific therapies that target the pathways leading to OS.
###end p 65
###begin title 66
Conclusion
###end title 66
###begin p 67
###xml 251 257 251 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3 </italic>
###xml 308 314 308 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC </italic>
###xml 370 375 370 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
In conclusion, through the screening of arrays we identified genes related to tumorigenesis. Three genes were validated with real-time RT-PCR and correlated with clinico-pathological parameters; whereby the clinical significance of over expression of THBS3 for tumor growth and progression, the necessity of SPARC for tumor growth and maintenance, and the potential for SPP1 as a biological marker of OS were demonstrated.
###end p 67
###begin title 68
Abbreviations
###end title 68
###begin p 69
IOP - Instituto de Oncologia Pediatrica
###end p 69
###begin p 70
GRAACC - Grupo de Apoio ao Adolescente e a Crianca com Cancer
###end p 70
###begin p 71
UNIFESP - Universidade Federal de Sao Paulo
###end p 71
###begin p 72
cDNA - complementary deoxyribonucleic acid
###end p 72
###begin p 73
PCR - polymerase chain reaction
###end p 73
###begin p 74
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3 </italic>
THBS3 - thrombospondin 3
###end p 74
###begin p 75
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC </italic>
SPARC - osteonectin, secreted protein acidic and rich in cysteine
###end p 75
###begin p 76
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
SPP1 - osteopontin, secreted phosphoprotein 1
###end p 76
###begin p 77
OS - osteosarcoma
###end p 77
###begin p 78
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ITGB4 </italic>
ITGB4 - integrin beta-4
###end p 78
###begin p 79
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTGF </italic>
CTGF - connective tissue growth factor
###end p 79
###begin p 80
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ITGA5 </italic>
ITGA5 - integrin alpha-5
###end p 80
###begin p 81
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VIL2 </italic>
VIL2 - villin 2, ezrin, cytovillin
###end p 81
###begin p 82
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ITGB2 </italic>
ITGB2 - integrin beta-2
###end p 82
###begin p 83
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LGALS3 </italic>
LGALS3 - galectin-3
###end p 83
###begin p 84
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADAM8 </italic>
ADAM8 - a disintegrin and metalloprotease domain 8
###end p 84
###begin p 85
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CLU </italic>
CLU - clusterin
###end p 85
###begin p 86
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FARP1 </italic>
FARP1 - pleckstrin domain-containing protein 1
###end p 86
###begin p 87
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CP </italic>
CP - ceruloplasmin
###end p 87
###begin p 88
RNA - ribonucleic acid
###end p 88
###begin p 89
DEPC water - diethylpyrocarbonate water
###end p 89
###begin p 90
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB </italic>
ACTB - beta-actin
###end p 90
###begin p 91
DNA- deoxyribonucleic acid
###end p 91
###begin p 92
###xml 44 72 <span type="species:ncbi:31271">Plasmodium chabaudi chabaudi</span>
pUC18 - hypothetical protein PC405478.00.0 [Plasmodium chabaudi chabaudi]
###end p 92
###begin p 93
RT-PCR - reverse transcriptase-polymerase chain reaction
###end p 93
###begin p 94
Ct - cycle threshold
###end p 94
###begin p 95
mRNA - messenger ribonucleic acid
###end p 95
###begin p 96
GEO - Gene Expression Omnibus
###end p 96
###begin p 97
NK cells - natural killer cells
###end p 97
###begin p 98
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMP</italic>
###xml 5 11 5 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS5 </italic>
COMP/THBS5 - cartilage oligomeric matrix protein
###end p 98
###begin p 99
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS1 </italic>
THBS1 - thrombospondin 1
###end p 99
###begin p 100
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VEGF </italic>
VEGF - vascular endothelial growth factor
###end p 100
###begin title 101
Competing interests
###end title 101
###begin p 102
The author(s) declare that they have no competing interests.
###end p 102
###begin title 103
Authors' contributions
###end title 103
###begin p 104
CADT: designed and performed experiments, analyzed data, and wrote manuscript
###end p 104
###begin p 105
MY, SCM and CHL: analyzed data and wrote the final manuscript
###end p 105
###begin p 106
AMJ: performed statistical analysis as required for the revised manuscript
###end p 106
###begin p 107
ASP: selected the cases and worked closely with SRCT
###end p 107
###begin p 108
SRCT, JADA, MZ and JAS: designed experiments, analyzed data, and wrote manuscript
###end p 108
###begin p 109
JAS: project leader, analyzed data, and wrote manuscript
###end p 109
###begin p 110
All authors read and approved the final manuscript.
###end p 110
###begin title 111
Pre-publication history
###end title 111
###begin p 112
The pre-publication history for this paper can be accessed here:
###end p 112
###begin p 113

###end p 113
###begin title 114
Acknowledgements
###end title 114
###begin p 115
This work was supported by awards from the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) and Grupo de Apoio ao Adolescente e a Crianca com Cancer (GRAACC) to C.A.D-T., Fundacao de Amparo e Pesquisa de Sao Paulo (FAPESP) and National Cancer Institute of Canada (NCIC) with funds from the Canadian Cancer Society.
###end p 115
###begin article-title 116
Osteosarcoma
###end article-title 116
###begin article-title 117
Censo Demografico
###end article-title 117
###begin article-title 118
Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival
###end article-title 118
###begin article-title 119
A preliminary report of neoadjuvant chemotherapy NSH-7 study in osteosarcoma: preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colony-stimulating factor
###end article-title 119
###begin article-title 120
Osteosarcoma necrosis following chemotherapy: innate biology versus treatment-specific
###end article-title 120
###begin article-title 121
Dissemination and growth of cancer cells in metastatic sites
###end article-title 121
###begin article-title 122
Application of proteomics in the study of tumor metastasis
###end article-title 122
###begin article-title 123
Quantitative monitoring of gene expression patterns with a complementary DNA microarray
###end article-title 123
###begin article-title 124
###xml 18 21 <span type="species:ncbi:10116">rat</span>
In vitro cultured rat islets express genes that both prevent and promote angiogenesis
###end article-title 124
###begin article-title 125
###xml 40 48 <span type="species:ncbi:9606">patients</span>
Endothelial cells in the bone marrow of patients with multiple myeloma
###end article-title 125
###begin article-title 126
Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas
###end article-title 126
###begin article-title 127
###xml 102 123 <span type="species:ncbi:813">Chlamydia trachomatis</span>
Chemokine expression patterns differ within anatomically distinct regions of the genital tract during Chlamydia trachomatis infection
###end article-title 127
###begin article-title 128
###xml 58 64 <span type="species:ncbi:10090">murine</span>
Metastasis-associated differences in gene expression in a murine model of osteosarcoma
###end article-title 128
###begin article-title 129
Superarray Bioscience Corporation: [http://www.superarray.com]
###end article-title 129
###begin article-title 130
NCBIs Gene Expression Omnibus [http://www.ncbi.nlm.nih.gov/geo/]
###end article-title 130
###begin article-title 131
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method
###end article-title 131
###begin article-title 132
Extracellular matrix: the thrombospondin family
###end article-title 132
###begin article-title 133
Thrombospondins
###end article-title 133
###begin article-title 134
Thrombospondins
###end article-title 134
###begin article-title 135
Osteonectin, a bone-specific protein linking mineral to collagen
###end article-title 135
###begin article-title 136
Matricellular proteins: extracellular modulators of cell function
###end article-title 136
###begin article-title 137
SPARC, a matricellular glycoprotein with important biological functions
###end article-title 137
###begin article-title 138
SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury
###end article-title 138
###begin article-title 139
Osteopontin expression and function: role in bone remodeling
###end article-title 139
###begin article-title 140
Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation
###end article-title 140
###begin article-title 141
The metastasis gene osteopontin: a candidate target for cancer therapy
###end article-title 141
###begin article-title 142
Osteopontin
###end article-title 142
###begin article-title 143
###xml 32 37 <span type="species:ncbi:9606">human</span>
Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance
###end article-title 143
###begin article-title 144
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice with a disruption of the thrombospondin 3 gene differ in geometric and biomechanical properties of bone and have accelerated development of the femoral head
###end article-title 144
###begin article-title 145
Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression
###end article-title 145
###begin article-title 146
Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density
###end article-title 146
###begin article-title 147
Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density
###end article-title 147
###begin article-title 148
###xml 121 128 <span type="species:ncbi:9606">patient</span>
Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas
###end article-title 148
###begin article-title 149
Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma
###end article-title 149
###begin article-title 150
Expression of thrombospondin-1 in cancer: a role in tumor progression
###end article-title 150
###begin article-title 151
Cell contact-dependent activation of alpha3beta1 integrin modulates endothelial cell responses to thrombospondin-1
###end article-title 151
###begin article-title 152
Osteonectin--a differentiation marker of bone cells
###end article-title 152
###begin article-title 153
Novel functions of the matricellular proteins osteopontin and osteonectin/SPARC
###end article-title 153
###begin article-title 154
Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas
###end article-title 154
###begin article-title 155
The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types
###end article-title 155
###begin article-title 156
Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression
###end article-title 156
###begin article-title 157
###xml 74 79 <span type="species:ncbi:9606">human</span>
SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells
###end article-title 157
###begin article-title 158
SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis
###end article-title 158
###begin article-title 159
International Hermelin brain tumor symposium on matricellular proteins in normal and cancer cell-matrix interactions
###end article-title 159
###begin article-title 160
Gene expression in osteoblastic cells
###end article-title 160
###begin article-title 161
###xml 81 86 <span type="species:ncbi:9606">human</span>
Expression of osteopontin mRNA by osteoclasts and osteoblasts in modelling adult human bone
###end article-title 161
###begin article-title 162
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human osteoclasts, not osteoblasts, deposit osteopontin onto resorption surfaces: an in vitro and ex vivo study of remodeling bone
###end article-title 162
###begin article-title 163
###xml 43 48 <span type="species:ncbi:9606">human</span>
Osteopontin expression and distribution in human carcinomas
###end article-title 163
###begin article-title 164
Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling
###end article-title 164
###begin article-title 165
Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma
###end article-title 165
###begin article-title 166
Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma
###end article-title 166
###begin article-title 167
Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer
###end article-title 167
###begin article-title 168
The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter
###end article-title 168
###begin title 169
Figures and Tables
###end title 169
###begin p 170
###xml 189 192 189 192 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A- </bold>
###xml 215 221 215 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3 </italic>
###xml 294 304 294 304 <bold xmlns:xlink="http://www.w3.org/1999/xlink">diagnosis </bold>
###xml 328 336 328 336 <bold xmlns:xlink="http://www.w3.org/1999/xlink">surgery </bold>
###xml 349 360 349 360 <bold xmlns:xlink="http://www.w3.org/1999/xlink">metastases </bold>
###xml 371 374 371 374 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B- </bold>
###xml 397 403 397 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC </italic>
###xml 476 486 476 486 <bold xmlns:xlink="http://www.w3.org/1999/xlink">diagnosis </bold>
###xml 510 518 510 518 <bold xmlns:xlink="http://www.w3.org/1999/xlink">surgery </bold>
###xml 531 542 531 542 <bold xmlns:xlink="http://www.w3.org/1999/xlink">metastases </bold>
###xml 552 555 552 555 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C- </bold>
###xml 578 583 578 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 656 666 656 666 <bold xmlns:xlink="http://www.w3.org/1999/xlink">diagnosis </bold>
###xml 690 698 690 698 <bold xmlns:xlink="http://www.w3.org/1999/xlink">surgery </bold>
###xml 711 722 711 722 <bold xmlns:xlink="http://www.w3.org/1999/xlink">metastases </bold>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
###xml 419 427 <span type="species:ncbi:9606">patients</span>
###xml 599 607 <span type="species:ncbi:9606">patients</span>
Relationship between gene expression and clinical evolution of disease. The box plot shows the median, upper and lower quartiles and minimum and maximum values for related gene expression. A- Relative expression of THBS3 in groups of OS patients represented by samples obtained from the biopsy diagnosis (n = 16), primary tumor surgery (n = 19) and metastases (n = 17) ; B- Relative expression of SPARC in groups of OS patients represented by samples obtained from the biopsy diagnosis (n = 26), primary tumor surgery (n = 16) and metastases (n = 13); C- Relative expression of SPP1 in groups of OS patients represented by samples obtained from the biopsy diagnosis (n = 16), primary tumor surgery (n = 20) and metastases (n = 17).
###end p 170
###begin p 171
###xml 179 182 179 182 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A- </bold>
###xml 283 288 283 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3</italic>
###xml 379 384 379 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">THBS3</italic>
###xml 386 389 386 389 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B- </bold>
###xml 490 495 490 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPARC</italic>
###xml 496 499 496 499 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C- </bold>
###xml 604 609 604 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPP1 </italic>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Overall, event-free survival and relapse-free survival analyses of OS patients correlated with gene expression profiling of either biopsy or primary tumor resection onset groups. A- Overall, event-free survival and relapse-free survival of biopsy onset group with over-expression of THBS3, and relapse-free survival of primary tumor resection onset group with over-expression of THBS3. B- Overall, event-free survival and relapse-free survival of biopsy onset group with over-expression of SPARC.C- Overall, event-free survival and relapse-free survival of biopsy onset group with over-expression of the SPP1 gene.
###end p 171
###begin p 172
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Clinico-pathological description of osteosarcoma patients.
###end p 172
###begin p 173
NOTE: Mean follow-up time was 34 months (range from 2 to 83 months)
###end p 173
###begin p 174
###xml 24 27 24 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
Pathway-focused GEArrays(R): Comparison of three of the up-regulated genes in osteosarcoma samples categorized as metastatic at diagnosis and non-metastatic at diagnosis
###end p 174
###begin p 175
###xml 0 3 0 3 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B, </bold>
###xml 23 26 23 26 <bold xmlns:xlink="http://www.w3.org/1999/xlink">S, </bold>
###xml 63 66 63 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink">M, </bold>
###xml 95 98 95 98 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C, </bold>
###xml 119 123 119 123 <bold xmlns:xlink="http://www.w3.org/1999/xlink">AE, </bold>
B, sample from biopsy, S, sample from primary tumor resection, M, sample from metastatic site, C, normal bone control, AE, absence of expression. The values are expressed as linear ratios against normal bone controls.
###end p 175

